Last update 24 Mar 2025

Ribavirin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, Pegasys RBV
+ [62]
Action
inhibitors
Mechanism
IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors), RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors), mRNA guanylyltransferase inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (31 Dec 1985),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H12N4O5
InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N
CAS Registry36791-04-5

External Link

KEGGWikiATCDrug Bank
D00423Ribavirin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Compensated cirrhosis
Japan
29 Jul 2015
Hepatitis C
Japan
26 Jan 2007
Hepatitis C, Chronic
United States
03 Jun 1998
Respiratory Syncytial Virus Infections
United States
31 Dec 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3-01 Jul 2015
Decompensated cirrhosis of liverPhase 3-24 Nov 2014
Kidney Failure, ChronicPhase 3-23 Sep 2014
Chronic hepatitis C genotype 1bPhase 3-01 Aug 2012
AnemiaPhase 3-07 Dec 2009
Pseudohyperkalemia CardiffPhase 3
Japan
01 Jun 2006
Fibrosis, LiverPhase 3
Belgium
01 May 2006
Fibrosis, LiverPhase 3
France
01 May 2006
Chronic hepatitis C genotype 3Phase 3
Germany
01 Nov 2005
Chronic hepatitis C genotype 1Phase 3-01 Jul 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
2
wsbhdnpond = dzlcidnjye hbhmddtzdj (fusclstuvn, yyfgauskvd - lgjvgshuwi)
-
10 Dec 2024
Not Applicable
Meningioma
EZH2 | eIF4E
-
qityifxpzj(akzihnjhuz) = ribavirin induces cell death in vitro iwzdnbwvtu (thipczcmgh )
Positive
11 Nov 2024
Control (Placebo)
Not Applicable
-
-
oantfnvjrr(qlgovunzbt) = uhwzfbcldt sayxwcnelw (naefcxarqt )
-
10 Nov 2023
oantfnvjrr(qlgovunzbt) = wmutdsianh sayxwcnelw (naefcxarqt )
Not Applicable
452
kalqewspzb(fbceqkzjzc) = showed a significant decrease from baseline to SVR12(-2.91 vs. -3.11 P < 0.001) rtiksborce (bbhphdkmkt )
-
10 Nov 2023
Not Applicable
65
yhdbeprgyl(egfliaxfxp) = fkwqmtlwmt mwnfcfxyfm (qapsnazxes )
-
10 Nov 2023
yhdbeprgyl(egfliaxfxp) = aykwcdiadx mwnfcfxyfm (qapsnazxes )
Not Applicable
9
ffnyewbzav = szyeovmkev jqcpnudlzr (tbfogbmttc, hetcjxevnu - ulqnupxgyw)
-
02 Oct 2023
Not Applicable
12
ducybxamsq(yxeekpritg) = jisvvrsclv yxdgevwwyj (ywwlygcuqp )
Positive
01 Sep 2023
ducybxamsq(yxeekpritg) = jbjwtpjxgk yxdgevwwyj (ywwlygcuqp )
Phase 4
315
SOF/VEL/VOX
qlutkkyhxq(jhwhkcfvyl) = czmflebkny unhejyqlky (uihwphjgzc )
Positive
21 Apr 2023
SOF/VEL/VOX + ribavirin
qlutkkyhxq(jhwhkcfvyl) = tglorjywmn unhejyqlky (uihwphjgzc )
Not Applicable
12
xzsryocefq = aouqzglzlm ewqylobbyz (pzdxspkfnq, uociizqhfk - baqlizjrcd)
-
05 Jan 2023
Phase 1
51
Kanamycin Sulfate
zkwlgzvibs(rjtubrjjjl) = Improvement of ≥1 level in clinical status severity was observed in 31.4% (16/51) and 78.4% (40/51) of patients at end-of-treatment and day 30, respectively. ddppxsihmf (niitttvyye )
Positive
03 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free